MBA MBA - Cardiol Therapeutics CEO Pres
| CRDL Stock | USD 1.54 0.08 4.94% |
Insider
MBA MBA is CEO Pres of Cardiol Therapeutics Class
| Address | 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 |
| Phone | 289-910-0850 |
| Web | https://www.cardiolrx.com |
Cardiol Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.81. The value of Return On Capital Employed is expected to slide to -1.1. At this time, Cardiol Therapeutics' Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 610.6 K this year, although the value of Non Currrent Assets Other are projected to rise to (0.95).Similar Executives
| Showing other executives | INSIDER Age | ||
| ChiHsin King | ABVC Biopharma | 76 | |
| Eugene Jiang | ABVC Biopharma | 38 | |
| Peter Rhode | HCW Biologics | 66 | |
| Walt Esq | Indaptus Therapeutics | 63 | |
| Javier Franco | Flora Growth Corp | 56 | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Pr Hazum | Painreform | N/A | |
| Jessie Casner | Flora Growth Corp | 36 | |
| Sigal Aviel | Painreform | 60 | |
| TsungShann Jiang | ABVC Biopharma | 70 | |
| Jeffrey Meckler | Indaptus Therapeutics | 57 | |
| CPA CPA | Flora Growth Corp | N/A | |
| Matthew Cohen | Flora Growth Corp | 58 | |
| Howard MD | ABVC Biopharma | 67 | |
| Leeds Chow | ABVC Biopharma | 35 | |
| Luis Merchan | Flora Growth Corp | 43 | |
| Hing Wong | HCW Biologics | 70 | |
| James Choe | Flora Growth Corp | 45 | |
| FCA FCA | Flora Growth Corp | 79 | |
| Boyan MD | Indaptus Therapeutics | 57 | |
Management Performance
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 |
Cardiol Therapeutics Leadership Team
Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew MD, Chief Development | ||
| Trevor Burns, Investor Relations | ||
| Bernard BSc, Chief Officer | ||
| MBA BSCPT, Vice Development | ||
| MBA MBA, CEO Pres | ||
| David MBA, CEO President | ||
| CA CMA, Corp CFO |
Cardiol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 116.38 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 814.79 K | ||||
| Price To Book | 16.79 X | ||||
| Price To Sales | 1,069 X | ||||
| Gross Profit | 78.76 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.